Ivabradine Crescent

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Crescent (Ivabradine)

Q: Who should not use Ivabradine Crescent?

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, and those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.

Ivabradine, the active ingredient in Ivabradine Crescent, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used to manage chronic stable angina and heart failure with reduced ejection fraction in adults.
GNH India supplies Ivabradine Crescent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Crescent Pharma Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac sinus node to reduce heart rate, benefiting conditions where excessive heart rate contributes to symptoms.
Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand.
Heart failure with reduced ejection fraction: improves exercise capacity and may reduce hospitalisations by controlling heart rate.
Symptomatic tachycardia in angina patients: provides rate control when beta‑blockers are insufficient or not tolerated.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which modulates spontaneous depolarisation. By blocking this inward sodium/potassium mixed current, the drug slows the pacemaker activity without affecting myocardial contractility, resulting in a controlled reduction of heart rate.

Side Effects

Common Side Effects

Bradycardia: resting heart rate may fall below 50 bpm.
Luminous phenomena (phosphenes): transient visual flashes.
Headache: mild to moderate intensity.
Dizziness or vertigo.
Fatigue or asthenia.
Nausea.

Serious or Rare Side Effects

Symptomatic severe bradycardia requiring medical attention.
Atrial fibrillation or other arrhythmias.
Visual disturbances such as blurred vision or retinal changes.
Hypotension with syncope.
Hepatic enzyme elevation.
Severe allergic reactions (rash, angioedema).

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline heart rate and cardiac function.
Monitor heart rate: ensure resting rate is ≥60 bpm before starting.
Avoid in severe hepatic impairment: contraindicated due to altered metabolism.
Use caution with concomitant beta‑blockers: risk of excessive bradycardia.
Do not combine with strong CYP3A4 inhibitors: may increase plasma concentrations.
Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly raise ivabradine levels.
Other bradycardic agents (high‑dose beta‑blockers, digoxin): may cause severe bradycardia.
Additional If channel inhibitors (e.g., ranolazine): additive heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment.

QT‑prolonging drugs: monitor ECG for interval changes.
CYP3A4‑inducing agents (e.g., rifampicin): may reduce efficacy, consider alternative therapy.

Frequently Asked Questions

Ivabradine Crescent is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the sinus node firing rate, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Inhibition of this current slows the depolarisation rate, leading to a controlled reduction in heart rate without affecting myocardial contractility.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s resting heart rate, clinical condition, and tolerance. The prescriber determines the appropriate starting dose and any subsequent adjustments, following local labeling and therapeutic guidelines.

Safety data for ivabradine during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient.

To request Ivabradine Crescent, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for heart‑rate control in angina and heart failure is the beta‑blocker class. Unlike beta‑blockers, ivabradine reduces heart rate without affecting contractility or blood pressure, making it useful when beta‑blockers are contraindicated or insufficient. However, ivabradine does not provide the anti‑ischemic benefits of some other agents like ranolazine.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight. Keep out of reach of children and do not use after the expiry date.

Ivabradine Crescent is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed and not double‑dose if a dose is missed.

The most serious adverse events include severe bradycardia (heart rate <50 bpm), symptomatic atrial fibrillation, significant hypotension, and visual disturbances such as blurred vision or retinal changes. Patients should seek immediate medical attention if they experience dizziness, fainting, palpitations, or visual symptoms.

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, and those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.